Please use this identifier to cite or link to this item:
|Title:||Mirtazapine: clinical advantages in the treatment of depression.|
|Authors:||Burrows, Graham D;Kremer, C M|
|Affiliation:||Department of Psychiatry, University of Melbourne, Austin, Australia.|
|Citation:||Journal of Clinical Psychopharmacology; 17 Suppl 1(): 34S-39S|
|Abstract:||Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety. Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients. In addition, mirtazapine was found to be equally effective as clomipramine in the treatment of severely depressed, hospitalized patients. The overall improvement with mirtazapine is seen after 1 week of treatment and is sustained throughout the treatment period. It is paralleled by an improvement in depressed mood, the core symptom of depressive illness. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic, adrenolytic, and serotonin-related side effects. The most frequently reported adverse events were transient sedation and weight gain.|
|Internal ID Number:||9090576|
Antidepressive Agents, Tricyclic.adverse effects.therapeutic use
Clinical Trials as Topic
Depressive Disorder.drug therapy
Eating Disorders.chemically induced
Mianserin.adverse effects.analogs & derivatives.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.